Response to Letter to the Editor Regarding "Abiraterone Acetate for the Treatment of Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal".

Pharmacoeconomics

Department of Clinical Epidemiology and Medical Technology Assessment (KEMTA), Maastricht University Medical Center, Maastricht, The Netherlands.

Published: June 2017

Download full-text PDF	Source
http://dx.doi.org/10.1007/s40273-017-0507-3	DOI Listing

Publication Analysis

response letter

letter editor

editor "abiraterone

"abiraterone acetate

acetate treatment

treatment chemotherapy-naïve

chemotherapy-naïve metastatic

metastatic castration-resistant

castration-resistant prostate

prostate cancer

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!